OncoMatch/Clinical Trials/NCT06354140
PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY
Is NCT06354140 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tegafur for esophageal squamous cell carcinoma.
Treatment: Tegafur — To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage YPT1N0M0, YPT2N0M0, YPT3N0M0, YPT4AN0M0 (8th UICC-TNM)
thoracic esophageal squamous cell carcinoma patients with residual pathologic primary site and lymph node positive (ypT1-4aN0M0) after surgery (8th UICC-TNM stage)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: immunotherapy — neoadjuvant
neoadjuvant immunotherapy combined with chemotherapy
Must have received: chemotherapy — neoadjuvant
neoadjuvant immunotherapy combined with chemotherapy
Must have received: surgery — radical resection
The operation was radical resection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06354140 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immunotherapy and chemotherapy.
What disease stage is eligible?
Stage YPT1N0M0 or YPT2N0M0 or YPT3N0M0 or YPT4AN0M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages